Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc. (SXTP)
Reporting Period: Quarter ended September 30, 2024 (Q3 2024)
Business Overview: A specialty pharmaceutical company focused on infectious diseases, primarily commercializing ARAKODA® (tafenoquine) for malaria prevention and developing treatments for babesiosis and other vector-borne diseases. The company is classified as a smaller reporting company and an emerging growth company.
Key Corporate Actions: The company executed a 1:12 reverse stock split effective August 12, 2024, to regain compliance with Nasdaq listing requirements. All share and per-share data in this filing have been retroactively adjusted.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Product Revenues | $135,293 | $51,188 | $365,939 | $127,892 |
| Total Net Revenue | $36,424 | $55,558 | $153,217 | $(117,427) |
| Gross Profit | $23,606 | $(20,008) | $110,040 | $(200,401) |
| Net Loss (Attributable to 60P) | $(2,159,785) | $4,183,198 | $(5,902,070) | $(1,753,418) |
| Cash and Equivalents | $3,300,688 | $2,218,540 | $3,300,688 | $2,218,540 |
| Total Assets | $7,420,893 | $7,783,771 | $7,420,893 | $7,783,771 |
| Accumulated Deficit | $(38,482,920) | $(32,580,850) | $(38,482,920) | $(32,580,850) |
Liquidity: As of September 30, 2024, the company held $3.3 million in cash and cash equivalents, plus $1.7 million in short-term investments. Management estimates sufficient funds to remain viable through June 30, 2025, excluding costs for the expanded access study for chronic babesiosis.
Material Changes vs. Prior Period
- Revenue Growth: Product revenues increased 164% quarter-over-quarter (Q3 2024 vs. Q3 2023) and 186% year-to-date, driven by organic growth in the U.S. civilian supply chain for babesiosis treatment and increased sales in Australia.
- Gross Margin Improvement: Gross margin improved significantly from a loss of (39.09%) in Q3 2023 to a profit of 17.45% in Q3 2024, attributed to fixed cost absorption as sales volume increased.
- Operating Expenses: Research and Development (R&D) expenses surged 256% in Q3 2024 compared to Q3 2023, primarily due to the recognition of $600,000 in share-based compensation for vendor services (Trevally) and costs related to the babesiosis clinical trial. General and Administrative (G&A) expenses decreased 7.5% due to lower stock-based compensation.
- Non-Operating Items: The company recognized a $1.68 million gain on the change in fair value of derivative liabilities for the nine months ended September 30, 2024, compared to a $95,324 gain in the prior year period. This relates to the contingent milestone payment liability to Knight Therapeutics.
- Capital Structure: The company raised approximately $7.1 million in financing activities during the first nine months of 2024, including a January offering, an At-The-Market (ATM) offering, and a September private placement.
Guidance, Outlook, and Risks
- Going Concern: The filing includes a "Going Concern" warning. The company has not demonstrated the ability to generate sufficient revenues to cover operating expenses and has accumulated significant losses. Continuation as a going concern is dependent on raising additional capital and achieving gross profitability.
- Strategic Pivot: The company suspended its Phase IIB COVID-19 study in late 2023 and has pivoted to focus on commercializing Arakoda for malaria and developing indications for babesiosis and other diseases.
- Clinical Pipeline:
- Babesiosis: IRB clearance received for an expanded use protocol for immunocompromised patients. A clinical trial with Yale University and Rhode Island Hospital is underway. Enrollment for the severe babesiosis trial (NCT06207370) is ongoing.
- Other: Preliminary data from North Carolina State University suggests a higher prevalence of chronic babesiosis than previously estimated. However, data from Monash University regarding tafenoquine for candidiasis does not currently support moving forward with a clinical program.
- Contingent Liabilities: The company has a contingent milestone payment obligation of $10 million to Knight Therapeutics upon the sale of Arakoda or a Change of Control. This is recorded as a derivative liability.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing a lack of full-time in-house personnel with technical knowledge for complex transactions and inadequate segregation of duties.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the management estimate that cash reserves will last through June 30, 2025, given the high burn rate and potential costs of the expanded access study.
- Revenue Concentration: Confirm the sustainability of revenue growth, noting that 92% of Q3 2024 product sales came from a single U.S. pharmaceutical distributor and sales are heavily dependent on discounts and rebates.
- Derivative Liability Valuation: Review the assumptions used to value the $623,762 derivative liability (contingent milestone payment), as changes in fair value significantly impact net income/loss.
- Share-Based Compensation: Assess the impact of non-cash share-based compensation expenses (e.g., the $600,000 R&D charge in Q3) on the company's reported operating losses.
- Internal Control Remediation: Monitor the company's progress in addressing the identified material weaknesses in internal controls over financial reporting.